Analysts Set LifeStance Health Group, Inc. (NASDAQ:LFST) Target Price at $8.60

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have been given a consensus recommendation of “Hold” by the six research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $8.83.

LFST has been the topic of several recent research reports. The Goldman Sachs Group increased their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Monday, March 4th. Morgan Stanley restated an “overweight” rating and set a $10.00 target price on shares of LifeStance Health Group in a research report on Monday. Barclays increased their target price on LifeStance Health Group from $7.00 to $8.00 and gave the stock an “underweight” rating in a research report on Thursday, February 29th. Finally, Jefferies Financial Group increased their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th.

Insider Activity

In other news, CFO David Bourdon sold 58,826 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $6.93, for a total transaction of $407,664.18. Following the transaction, the chief financial officer now directly owns 433,856 shares of the company’s stock, valued at $3,006,622.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO David Bourdon sold 58,826 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $6.93, for a total transaction of $407,664.18. Following the completion of the sale, the chief financial officer now directly owns 433,856 shares in the company, valued at $3,006,622.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Paula Cipollone sold 13,996 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $6.93, for a total transaction of $96,992.28. Following the sale, the insider now owns 293,562 shares of the company’s stock, valued at $2,034,384.66. The disclosure for this sale can be found here. Over the last three months, insiders have sold 245,463 shares of company stock valued at $1,786,868. 8.50% of the stock is currently owned by insiders.

Institutional Trading of LifeStance Health Group

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Assetmark Inc. lifted its holdings in LifeStance Health Group by 21.6% in the fourth quarter. Assetmark Inc. now owns 11,895 shares of the company’s stock worth $93,000 after buying an additional 2,114 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in LifeStance Health Group in the third quarter worth about $34,000. Sunbelt Securities Inc. purchased a new stake in LifeStance Health Group in the third quarter worth about $34,000. Charles Schwab Investment Management Inc. lifted its holdings in LifeStance Health Group by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 744,617 shares of the company’s stock worth $5,830,000 after buying an additional 5,112 shares during the period. Finally, Keybank National Association OH lifted its holdings in shares of LifeStance Health Group by 37.9% during the third quarter. Keybank National Association OH now owns 26,587 shares of the company’s stock valued at $183,000 after purchasing an additional 7,303 shares during the last quarter. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

LifeStance Health Group Stock Performance

LFST stock opened at $6.17 on Monday. The firm has a market cap of $2.35 billion, a PE ratio of -12.10 and a beta of 1.34. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.20. The business has a 50 day moving average of $6.46 and a 200-day moving average of $6.53. LifeStance Health Group has a 12-month low of $4.74 and a 12-month high of $9.59.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.03). LifeStance Health Group had a negative net margin of 17.64% and a negative return on equity of 12.66%. The firm had revenue of $280.60 million during the quarter, compared to analysts’ expectations of $263.14 million. As a group, sell-side analysts expect that LifeStance Health Group will post -0.3 earnings per share for the current year.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.